FOLH1 and prostate carcinoma: Table 1 summarizes a selected list of studies, which investigated the effect of PSMA PET on management decisions in patients with recurrent prostate cancer initially treated with RT or RP [21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48].